{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T03:21:11Z","timestamp":1788751271511,"version":"build-2803163510"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"16","license":[{"start":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T00:00:00Z","timestamp":1697500800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T00:00:00Z","timestamp":1697500800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1007\/s40265-023-01952-y","type":"journal-article","created":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T09:02:20Z","timestamp":1697533340000},"page":"1545-1549","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Tafolecimab: First Approval"],"prefix":"10.1007","volume":"83","author":[{"given":"Susan J.","family":"Keam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,17]]},"reference":[{"issue":"25","key":"1952_CR1","first-page":"e1082","volume":"139","author":"SM Grundy","year":"2019","unstructured":"Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082\u2013143.","journal-title":"Circulation"},{"issue":"9","key":"1952_CR2","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1161\/CIR.0000000000001168","volume":"148","author":"SS Virani","year":"2023","unstructured":"Virani SS, Newby LK, Arnold SV, et al. 2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2023;148(9):e9\u2013119.","journal-title":"Circulation"},{"issue":"3","key":"1952_CR3","first-page":"221","volume":"51","author":"JJ Li","year":"2023","unstructured":"Li JJ, Zhao SP, Gao RL, on behalf of the Joint Committee on the Chinese Guidelines for Lipid Management. Chinese guidelines for lipid management (2023). Chin J Cardiol. 2023;51(3):221\u201355.","journal-title":"Chin J Cardiol."},{"issue":"4","key":"1952_CR4","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.jacasi.2023.06.002","volume":"3","author":"JJ Li","year":"2023","unstructured":"Li JJ. Tafolecimab, a novel member of PCSK9 monoclonal antibodies, is worth expecting in a Chinese population. JACC Asia. 2023;3(4):646\u20138.","journal-title":"JACC Asia."},{"key":"1952_CR5","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1146\/annurev-med-042716-091351","volume":"69","author":"CN Hess","year":"2018","unstructured":"Hess CN, Low Wang CC, Hiatt WR. PCSK9 inhibitors: mechanisms of action, metabolic effects, and clinical outcomes. Annu Rev Med. 2018;69:133\u201345.","journal-title":"Annu Rev Med"},{"key":"1952_CR6","unstructured":"Innovent. Tafolecimab: Chinese prescribing information. 2023. https:\/\/www.innoventbio.com\/. Accessed 11 Sep 2023."},{"key":"1952_CR7","unstructured":"Innovent. Innovent announces the NMPA approval of SINTBILO\u00ae (tafolecimab injection) for the treatment of adult patients with primary hypercholesterolemia and mixed dyslipidemia [media release]. 16 August 2023. https:\/\/www.innoventbio.com\/."},{"key":"1952_CR8","unstructured":"National Medical Products Administration. The State Drug Administration approves tafolecimab injection for marketing. 2023. https:\/\/www.nmpa.gov.cn\/yaowen\/ypjgyw\/20230816171810151.html. Accessed 11 Sep 2023."},{"issue":"3","key":"1952_CR9","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.jacasi.2021.09.002","volume":"1","author":"Y Cui","year":"2021","unstructured":"Cui Y, Zhao X, Qi L, et al. A potential long-acting LDL-cholesterol-lowering PCSK9 monoclonal antibody: randomized, placebo-controlled phase 1 studies. JACC Asia. 2021;1(3):411\u20135.","journal-title":"JACC Asia."},{"key":"1952_CR10","doi-asserted-by":"crossref","unstructured":"Huo Y, Li Y, Zhang P, et al. Efficacy and safety of tafolecimab in Chinese patients with non-familial hypercholesterolemia (CREDIT-1): a 48-week randomized, double-blind, placebo-controlled phase 3 trial [abstract no. 10111]. Circulation. 2022;146(Suppl_1).","DOI":"10.1161\/circ.146.suppl_1.10111"},{"issue":"77","key":"1952_CR11","first-page":"1","volume":"21","author":"M Chai","year":"2023","unstructured":"Chai M, He Y, Zhao W, et al. Efficacy and safety of tafolecimab in Chinese patients with heterozygous familial hypercholesterolemia: a randomized, double-blind, placebo-controlled phase 3 trial (CREDIT-2). BMC Med. 2023;21(77):1\u201311.","journal-title":"BMC Med"},{"issue":"4","key":"1952_CR12","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.jacasi.2023.04.011","volume":"3","author":"L Qi","year":"2023","unstructured":"Qi L, Liu D, Qu Y, et al. Tafolecimab in Chinese patients with hypercholesterolemia (CREDIT-4): a randomized, double-blind, placebo-controlled phase 3 trial. JACC Asia. 2023;3(4):636\u201345.","journal-title":"JACC Asia."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-023-01952-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-023-01952-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-023-01952-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T11:30:27Z","timestamp":1699011027000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-023-01952-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,17]]},"references-count":12,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["1952"],"URL":"https:\/\/doi.org\/10.1007\/s40265-023-01952-y","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,17]]},"assertion":[{"value":"17 October 2023","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Susan J. Keam is a contracted employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}